Why it may matterVerify against the original reporting
Strong topline growth, sustained gross margin expansion, and a clear FY27 revenue target create a favorable fundamental backdrop; a positive guidance raise often precedes multiple expansion, especially with cash richness and strategic partnerships. However, continued losses and non-GAAP adjustments pose execution risk; the balance of growth vs. profitability will be key.
AI summary
What happened, with direct paths to the underlying reporting
Kestra Medical Technologies posted a strong Q4 FY26 with revenue of $28.6 million (up 66% YoY) and FY26 revenue of $95.1 million (up 59%), while expanding gross margins to 54.8% for Q4 and 51.4% for the year. The company guided FY27 revenue to $137 million (+44%), supported by a Biobeat collaboration and positive FDA post-approval data. With $262.2 million in cash and improved operating cash flow, Kestra tilts toward accelerated market expansion.
Q4'26 revenue $28.6M, up 66%; FY26 revenue $95.1M, up 59%.
Q4'26 gross margin 54.8%; FY26 gross margin 51.4%, driven by volume and in-network mix.
FY27 revenue guide $137M, +44%; Biobeat collaboration and FDA post-approval data highlighted.
ASSURE prescriptions: 6,357 in Q4; 20,720 in FY26; 18,000 patients protected in FY26.
Cash and investments $262.2M as of 4/30/2026; net cash used in ops improved.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
